Medication: 3 different doses of Emtricitabine/Raltegravir and Maraviroc/Tenofovir
Duration: Approximately 2 months, both inpatient and outpatient visits
Call: Heather Prince 843-6848
A5311 A Phase I Clinical Trial of the Pharmacokinetics of High-dose Daily Rifapentine, Given as a Single Dose or in Divided Doses to Healthy Volunteers
Question: To evaluate two strategies for maximizing daily exposure to rifapentine (RPT)
Population: Healthy males and females, ages 18-65
Medication: 3 different doses of rifapentine
Duration: 63-77 days
Call: Becky Straub 919-843-9975
HPTN 069 – NEXT PREP Novel Exploration of Therapeutics for PREP, A phase II randomized, double-blind, study of the safety and tolerability of four antiretroviral drug regiments for Pre-Exposure Prophylaxis (PrEP) to Prevent HIV Transmission.
Question: To assess the safety and tolerability of Maraviroc (MVC), Maraviroc+ Emtricitabine (FTC), Maraviroc + Tenofovir disoproxil fumarate (TDF), and Tenofovir disoproxil fumarate + Emtricitabine in each study arm.